PCV-2 Antigen Filtration for Multivalent Vaccine Compatibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Porcine Circovirus Type II (PCV-2) exhibit virucidal activity that exceeds regulatory limits, preventing their combination with other antigens in multivalent compositions and posing challenges in reducing the impact of PCV-2 and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections.
Innovation Solution
A method involving the production of PCV-2 antigenic compositions using semi-permeable membranes to filter out virus-like particles of the ORF-2 protein, reducing virucidal activity by concentrating the antigen and exchanging it with a non-virucidal solution, thereby minimizing the loss of live virus or bacteria when combined with other antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If PCV-2 antigenic compositions are produced using conventional methods, then the antigen concentration is sufficient for immunogenicity, but the virucidal activity exceeds regulatory limits and prevents combination with other antigens
Solution Approach 1:
The patent extracts and removes the virucidal component (free virus particles) from the PCV-2 antigenic composition through filtration and purification steps, retaining only the antigenic components needed for immunization while eliminating the harmful virucidal activity that prevents combination with other antigens
Solution Approach 2:
The patent changes the physical and chemical parameters of the composition through controlled purification processes, adjusting the concentration of antigenic components while reducing virucidal activity to acceptable levels, thereby enabling combination with other antigens while maintaining immunogenicity
2Reliability
If PCV-2 antigen is concentrated to improve immunogenicity, then the vaccine efficacy increases, but the virucidal activity increases beyond regulatory limits
Solution Approach 1:
The patent segments the PCV-2 composition into distinct components through purification, separating the immunogenic antigenic components from the virucidal free virus particles, allowing independent control and optimization of each component's concentration and activity
Solution Approach 2:
The patent uses purification intermediaries such as filtration membranes and buffer solutions as mediators to selectively remove virucidal components while preserving and concentrating the antigenic components, achieving the desired balance between immunogenicity and reduced virucidal activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly reduces virucidal activity to acceptable levels, allowing for the safe combination of PCV-2 antigens with other immunogens and enhancing the immunogenicity of the resulting compositions.
Implementation Method 1
removing at least a portion of the first liquid from the PCV-2 antigen by a filtration step utilizing a filter, wherein the filter includes a semi-permeable membrane having an average pore size that is smaller than the PCV-2 antigen
Implementation Method 2
The portion of the first liquid is removed from the PCV-2 antigen by an exchange of the portion of the first liquid against a second liquid, wherein the exchange of the portion of the first liquid with the second liquid comprises the steps of: adding the second liquid to the first liquid which contains the PCV-2 antigen; and concentrating the PCV-2 antigen by removing a portion of the first and second liquids
Data Source
Figure 1
AI summary
The present invention provides methods of reducing the vircidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity.